Hepatorenal syndrome (HRS), the extreme manifestation of renal impairment in patients with
cirrhosis, is characterized by reduction in renal blood flow and glomerular filtration rate …

Rifaximin is an oral nonsystemic antibiotic with minimal gastrointestinal absorption and
broad‐spectrum antibacterial activity covering both gram‐positive and gram‐negative …

Decreased muscle mass and function, also known as sarcopenia, is common in patients
with cirrhosis and is associated with a poor prognosis. Although the pathogenesis of this …

Strategies to prevent infection and improve outcomes in patients with cirrhosis. HAV,
hepatitis A virus; HBV, hepatitis B virus; COVID-19, novel coronavirus disease 2019; NSBB …

The current approaches to the management of patients with decompensated cirrhosis are
based on targeted strategies aimed at preventing or treating specific complications of the …

Patients with decompensated cirrhosis are currently managed through targeted strategies
aimed at preventing or treating specific complications. In contrast, a disease-modifying agent …

Hepatorenal syndrome (HRS), a progressive but potentially reversible deterioration of
kidney function, remains a major complication in patients with advanced cirrhosis, often …

Background Approximately 2.5% of all hospitalisations in people with liver cirrhosis are for
spontaneous bacterial peritonitis. Spontaneous bacterial peritonitis is associated with …

METHODS: We searched PubMed, Embase, and the Cochrane Registry from inception to
May 2019 to identify randomized controlled trials of patients with liver cirrhosis that assessed …

Background and aims Rifaximin has been recommended as a prophylactic drug for hepatic
encephalopathy (HE) and spontaneous bacterial peritonitis (SBP). This study aims to …